Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLGA-ORM is a polymeric nanoformulation consisting of the non-steroidal selective estrogen receptor modulator (SERM) ormeloxifene (ORM) encapsulated within poly(lactic-co-glycolic acid) (PLGA) nanoparticles. Developed by researchers at the University of Tennessee Health Science Center and Sanford Research, this formulation is designed to enhance the therapeutic efficacy of ormeloxifene for cervical cancer. The PLGA matrix provides a biodegradable delivery system that improves cellular uptake via endocytosis and increases the anti-proliferative and anti-clonogenic potential of the drug. In preclinical orthotopic mouse models of cervical cancer, PLGA-ORM demonstrated superior anti-tumor activity compared to free ormeloxifene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PLGA-ORM.